-
公开(公告)号：US20210061814A1
公开(公告)日：2021-03-04
申请号：US16924037
申请日：2020-07-08
申请人： St. Louis College of Pharmacy , University of Southern California , The University of North Carolina at Chapel Hill , Memorial Sloan Kettering Cancer Center , University of Florida Research Foundation, Incorporated , Memorial Sloan Kettering Cancer Center
发明人： Susruta MAJUMDAR , Vsevolod KATRITCH , Bryan ROTH , JAY MCLAUGHLIN , Saheem ZAIDI , Gavril W. PASTERNAK , Rajendra UPRETY
IPC分类号： C07D489/00 , C07D221/28
摘要： In some aspects, the present disclosure provides compounds of the formula: wherein the variables are as defined herein. In some embodiments, these compounds may be used to reduce the pain of a patient. These compounds may be used in pain relief and show an improved pharmaceutical profile relative to other commonly used opiates and opioid derivatives.
-
公开(公告)号：US11613547B2
公开(公告)日：2023-03-28
申请号：US16924037
申请日：2020-07-08
申请人： University of Health Sciences & Pharmacy in St. Louis , University of Southern California , The University of North Carolina at Chapel Hill , Memorial Sloan Kettering Cancer Center , University of Florida Research Foundation, Incorporated , Memorial Sloan Kettering Cancer Center
发明人： Susruta Majumdar , Vsevolod Katritch , Bryan Roth , Jay McLaughlin , Saheem Zaidi , Gavril W. Pasternak , Rajendra Uprety
IPC分类号： C07D489/00 , C07D221/28
摘要： In some aspects, the present disclosure provides compounds of the formula: wherein the variables are as defined herein. In some embodiments, these compounds may be used to reduce the pain of a patient. These compounds may be used in pain relief and show an improved pharmaceutical profile relative to other commonly used opiates and opioid derivatives.
-
公开(公告)号：US11633401B2
公开(公告)日：2023-04-25
申请号：US17258054
申请日：2019-07-03
发明人： Marcus Ruscetti , John P. Morris, IV , Scott Lowe
IPC分类号： A61K31/535 , A61P35/00 , A61K31/145 , A61K31/18 , A61K31/185 , A61K31/4184 , A61K31/44 , A61K31/4412 , A61K31/4523 , A61K31/506 , A61K31/519
摘要： The present technology provides methods for treating pancreatic cancer using a MEK inhibitor and a CDK4/6 inhibitor. Also disclosed herein are methods for increasing patient responsiveness to chemotherapeutic and/or immunotherapeutic regimes for pancreatic cancer. Kits for use in practicing the methods are also provided.
-
公开(公告)号：US20230123747A1
公开(公告)日：2023-04-20
申请号：US17581010
申请日：2022-01-21
发明人： Gabriela Chiosis , Pengrong Yan , Pallav Patel , Hardik J. Patel , Tony Taldone , Chenghua Yang , Weilin Sun , Stefan O. Ochiana
IPC分类号： C07D473/34 , G16B35/00 , G16C20/60 , G16C20/64 , C07D519/00 , G01N33/50
摘要： The disclosure relates to novel selective Grp94 inhibitors, compositions comprising an effective amount of such compounds, and methods to treat or prevent a condition, such as cancer, comprising administering to an animal in need thereof an effective amount of such compounds.
-
公开(公告)号：US20230117572A1
公开(公告)日：2023-04-20
申请号：US17790091
申请日：2020-12-29
发明人： Xuejun JIANG , Derek TAN , Deguang LIANG , Pui-Mun WONG , Takao SUZUKI
IPC分类号： C07D471/04 , A61K45/06
摘要： The present technology is directed to compounds, compositions, and methods related to inhibition of ULK1 and treatment of cancers therefrom.
-
公开(公告)号：US20230087125A1
公开(公告)日：2023-03-23
申请号：US18049876
申请日：2022-10-26
摘要： The presently disclosed subject matter provides methods for treating neoplasia using cells comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR)) that specifically targets CD127.
-
公开(公告)号：US11607249B2
公开(公告)日：2023-03-21
申请号：US16069767
申请日：2017-01-13
发明人： Yukio Sonoda , Paul Booth , Jon Massucci
摘要： An exemplary apparatus, according to an exemplary embodiment of the present disclosure, can include, for example, a uterine manipulator having a clamp arrangement having a first tip(s) and a second tip(s), and a colpotomy ring arrangement coupled to the clamp arrangement on or at the first tip(s), and including an opening(s) in an outer surface thereof for insertion of the second tip(s) therethrough when the clamp arrangement is in a closed position. In some exemplary embodiments of the present disclosure, the clamp arrangement can include a uterine manipulator. The first tip(s) can include a plurality of removable tips, where each of the tips can have a different length from one another. In certain exemplary embodiments of the present disclosure, the first tip(s) can have a variable length.
-
公开(公告)号：US20230082710A1
公开(公告)日：2023-03-16
申请号：US17985114
申请日：2022-11-10
发明人： Thomas Fuchs , Gabriele Campanella
摘要： The present disclosure is directed to systems and methods for classifying biomedical images. A feature classifier may generate a plurality of tiles from a biomedical image. Each tile may correspond to a portion of the biomedical image. The feature classifier may select a subset of tiles from the plurality of tiles by applying an inference model. The subset of tiles may have highest scores. Each score may indicate a likelihood that the corresponding tile includes a feature indicative of the presence of the condition. The feature classifier may determine a classification result for the biomedical image by applying an aggregation model. The classification result may indicate whether the biomedical includes the presence or lack of the condition.
-
公开(公告)号：US20230069622A1
公开(公告)日：2023-03-02
申请号：US17705798
申请日：2022-03-28
IPC分类号： A61K31/4439 , A61K31/337 , A61K31/7068 , A61P35/00 , A61K31/404 , A61K31/7048 , A61K45/06 , C12Q1/48 , G01N33/574
摘要： Disclosed is a method for enhancing tumor response to chemotherapy, the method comprising administering a short-acting anti-angiogenic agent (AAA) capable of activating ASMase to a subject afflicted with a solid tumor, and thereby creating a time interval of increased susceptibility of said tumor to one or more chemotherapeutic agents, followed by administration of at least one chemotherapeutic agent within the interval. The interval can be defined in terms of a short-duration activation of ASMase signaling by the AAA. Disclosed are also methods for predicting the tumor response in a patient afflicted with a solid tumor to a chemotherapeutic agent, using as an indicator of the response ASMase level or activity (or ceramide level) in the patient following the administration of the chemotherapeutic agent to the patient, or dynamic IVIM based DW-MRI to measure perfusion alterations following administration of the chemotherapeutic agent.
-
公开(公告)号：US20230057304A1
公开(公告)日：2023-02-23
申请号：US17681342
申请日：2022-02-25
发明人： Liang DENG , Stewart SHUMAN , Jedd WOLCHOK , Taha MERGHOUB , Weiyi WANG , Peihong DAI , Ning YANG
IPC分类号： A61K39/395 , A61K39/00 , C12N15/86 , C07K16/28 , C07K14/52 , A61K35/768 , A61P35/00 , A61K9/00
摘要： The present disclosure relates generally to the fields of oncology, virology and immunotherapy. It concerns poxviruses, specifically the highly attenuated modified vaccinia virus Ankara (MVA), and a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVAΔE3L), each further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L) or GM-CSF. The disclosure relates to use of the foregoing recombinant viruses as cancer immunotherapeutic agents. The foregoing recombinant poxviruses can also be used in combination with immune checkpoint blockade therapy.
-
-
-
-
-
-
-
-
-
搜索结果
1043 条记录 (耗时 0.051 秒)